U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C19H14F2N6O
Molecular Weight 380.3509
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TALAZOPARIB

SMILES

CN1N=CN=C1[C@@H]2[C@H](NC3=CC(F)=CC4=C3C2=NNC4=O)C5=CC=C(F)C=C5

InChI

InChIKey=HWGQMRYQVZSGDQ-HZPDHXFCSA-N
InChI=1S/C19H14F2N6O/c1-27-18(22-8-23-27)15-16(9-2-4-10(20)5-3-9)24-13-7-11(21)6-12-14(13)17(15)25-26-19(12)28/h2-8,15-16,24H,1H3,(H,26,28)/t15-,16-/m1/s1

HIDE SMILES / InChI
Molecular Formula C19H14F2N6O
Molecular Weight 380.3509
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Approval Year

Unknown
86413
Substance Class Chemical
Created
by admin
on Sat Dec 16 08:20:43 UTC 2023
Edited
by admin
on Sat Dec 16 08:20:43 UTC 2023
Record UNII
9QHX048FRV
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TALAZOPARIB
INN   USAN  
USAN   INN  
Official Name English
BMN 673
Code English
talazoparib [INN]
Common Name English
3H-PYRIDO(4,3,2-DE)PHTHALAZIN-3-ONE, 5-FLUORO-8-(4-FLUOROPHENYL)-2,7,8,9-TETRAHYDRO-9-(1-METHYL-1H-1,2,4-TRIAZOL-5-YL)-, (8S,9R)-
Systematic Name English
TALAZOPARIB [USAN]
Common Name English
PF-06944076
Code English
BMN-673
Code English
(8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one
Systematic Name English
Talazoparib [WHO-DD]
Common Name English
TALAZOPARIB [MI]
Common Name English
LT-673
Code English
Classification Tree Code System Code
NCI_THESAURUS C62554
Created by admin on Sat Dec 16 08:20:43 UTC 2023 , Edited by admin on Sat Dec 16 08:20:43 UTC 2023
WHO-ATC L01XX60
Created by admin on Sat Dec 16 08:20:43 UTC 2023 , Edited by admin on Sat Dec 16 08:20:43 UTC 2023
NDF-RT N0000191623
Created by admin on Sat Dec 16 08:20:43 UTC 2023 , Edited by admin on Sat Dec 16 08:20:43 UTC 2023
Code System Code Type Description
USAN
BC-63
Created by admin on Sat Dec 16 08:20:43 UTC 2023 , Edited by admin on Sat Dec 16 08:20:43 UTC 2023
PRIMARY
DAILYMED
9QHX048FRV
Created by admin on Sat Dec 16 08:20:43 UTC 2023 , Edited by admin on Sat Dec 16 08:20:43 UTC 2023
PRIMARY
RXCUI
2099704
Created by admin on Sat Dec 16 08:20:43 UTC 2023 , Edited by admin on Sat Dec 16 08:20:43 UTC 2023
PRIMARY
CAS
1207456-01-6
Created by admin on Sat Dec 16 08:20:43 UTC 2023 , Edited by admin on Sat Dec 16 08:20:43 UTC 2023
PRIMARY
FDA UNII
9QHX048FRV
Created by admin on Sat Dec 16 08:20:43 UTC 2023 , Edited by admin on Sat Dec 16 08:20:43 UTC 2023
PRIMARY
EVMPD
SUB180394
Created by admin on Sat Dec 16 08:20:43 UTC 2023 , Edited by admin on Sat Dec 16 08:20:43 UTC 2023
PRIMARY
LACTMED
Talazoparib
Created by admin on Sat Dec 16 08:20:43 UTC 2023 , Edited by admin on Sat Dec 16 08:20:43 UTC 2023
PRIMARY
WIKIPEDIA
Talazoparib
Created by admin on Sat Dec 16 08:20:43 UTC 2023 , Edited by admin on Sat Dec 16 08:20:43 UTC 2023
PRIMARY
PUBCHEM
135565082
Created by admin on Sat Dec 16 08:20:43 UTC 2023 , Edited by admin on Sat Dec 16 08:20:43 UTC 2023
PRIMARY
MERCK INDEX
m12100
Created by admin on Sat Dec 16 08:20:43 UTC 2023 , Edited by admin on Sat Dec 16 08:20:43 UTC 2023
PRIMARY
INN
9868
Created by admin on Sat Dec 16 08:20:43 UTC 2023 , Edited by admin on Sat Dec 16 08:20:43 UTC 2023
PRIMARY
EPA CompTox
DTXSID001025928
Created by admin on Sat Dec 16 08:20:43 UTC 2023 , Edited by admin on Sat Dec 16 08:20:43 UTC 2023
PRIMARY
DRUG BANK
DB11760
Created by admin on Sat Dec 16 08:20:43 UTC 2023 , Edited by admin on Sat Dec 16 08:20:43 UTC 2023
PRIMARY
NCI_THESAURUS
C95733
Created by admin on Sat Dec 16 08:20:43 UTC 2023 , Edited by admin on Sat Dec 16 08:20:43 UTC 2023
PRIMARY
ChEMBL
CHEMBL3137320
Created by admin on Sat Dec 16 08:20:43 UTC 2023 , Edited by admin on Sat Dec 16 08:20:43 UTC 2023
PRIMARY
SMS_ID
100000166294
Created by admin on Sat Dec 16 08:20:43 UTC 2023 , Edited by admin on Sat Dec 16 08:20:43 UTC 2023
PRIMARY
Related Record Type Details
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
In vitro, protein binding of talazoparib is 74% and is independent of talazoparib concentration.
BINDING
Structure of TALAZOPARIB TOSYLATE
SALT/SOLVATE -> PARENT
ATP-BINDING CASSETTE SUB-FAMILY G MEMBER 2
TRANSPORTER -> SUBSTRATE
Co-administration with BCRP inhibitors may increase talazoparib exposure.
MULTIDRUG RESISTANCE PROTEIN 1
TRANSPORTER -> SUBSTRATE
Co-administration of talazoparib with certain P-gp inhibitors including amiodarone, carvedilol, clarithromycin, itraconazole, and verapamil in the clinical studies (PRP-001, PRP-002, ABRAZO and EMBRACA) increased talazoparib exposure by 44.7%, in conjunction with an increased rate of Talzenna dose reductions (41%).
Structure of TALAZOPARIB
EXCRETED UNCHANGED
FECAL
Structure of TALAZOPARIB
EXCRETED UNCHANGED
POLY (ADP-RIBOSE) POLYMERASE 2
TARGET -> INHIBITOR
IC50
Related Record Type Details
Structure of TALAZOPARIB
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Tmax PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966